Combined DNA vaccines formulated either in DDA or in saline protect cattle from Mycobacterium bovis infection.
We tested the effectiveness of combined DNA vaccines encoding antigens Ag85B, MPT64 and MPT83 from Mycobacterium tuberculosis on cattle. Our results showed that calves treated with combined DNA vaccines in the presence of dimethyldioctyldecyl ammonium bromide (DDA) or saline elicited a strong gamma interferon (IFN-gamma) response 1 or 2 months after the third vaccination. All three antigens induced substantial levels of IFN-gamma production 1 month after the bacterial challenge, when the BCG-driven IFN-gamma levels dropped to less than one third of their peak values. Animals receiving combined DNA vaccines produced highest amounts of IgG antibody titer 2 months after the third vaccination. Steady state low IgG levels were found 2 months after bacterial challenge. A few small lung and lymph node lesions were detected in 1/5 animals treated with combined DNA vaccines, whereas 3/5 of BCG-treated and 5/5 of vector-control calves showed larger and significantly more lesions. About 70- to 100-fold fewer bacteria were found in the lungs and lymph nodes of combined DNA vaccine-treated animals compared to those of the control group. Histopathological analyses showed that vaccinated calves possessed substantially improved post-infection lung and lymph node pathology relative to the controls. Our data indicate that combined DNA vaccines may be used in cattle to combat bovine tuberculosis.
Cai
H
H
National Laboratory of Protein Engineering and Plant Genetic Engineering, Peking University, Beijing 100871, China. hcai@pku.edu.cn
Tian
X
X
Hu
X D
XD
Li
S X
SX
Yu
D H
DH
Zhu
Y X
YX
D000818:Animals; D000918:Antibody Specificity; D000942:Antigens, Bacterial / Q000235:genetics; D001500:BCG Vaccine / Q000276:immunology*; D002417:Cattle; D002626:Chemistry, Pharmaceutical; D003634:DDT / Q000031:analogs & derivatives* / Q000737:chemistry*; D004797:Enzyme-Linked Immunosorbent Assay; D005079:Excipients / Q000737:chemistry*; D005822:Genetic Vectors; D007074:Immunoglobulin G / Q000032:analysis; D007371:Interferon-gamma / Q000032:analysis; D008168:Lung / Q000382:microbiology / Q000473:pathology; D008198:Lymph Nodes / Q000382:microbiology / Q000473:pathology; D008297:Male; D009163:Mycobacterium bovis / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014374:Tuberculin Test; D014380:Tuberculosis, Bovine / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D017778:Vaccines, Combined / Q000737:chemistry / Q000276:immunology; D019444:Vaccines, DNA / Q000737:chemistry / Q000276:immunology
D000942:Antigens, Bacterial; D001500:BCG Vaccine; D005079:Excipients; D007074:Immunoglobulin G; D017778:Vaccines, Combined; D019444:Vaccines, DNA; D007371:Interferon-gamma; C000849:bis(p-chlorophenyl)acetic acid; D003634:DDT